Canvas Category OEM : Pharmaceutical
We aspire to be the premier research-intensive biopharmaceutical company in the world. For over 130 years, Merck (known as MSD outside the U.S. and Canada) has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, we continue to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases, such as HIV and Ebola, and emerging animal diseases.
🧀 Next Time You Buy Parmesan, Watch Out for the Microchip
Italian producers of parmesan cheese have been fighting against imitations for years. Now, makers of Parmigiano-Reggiano, as the original parmesan cheese is officially called, are slapping the microchips on their 90-pound cheese wheels as part of an endless cat-and-mouse game between makers of authentic and fake products.
The new silicon chips, made by Chicago-based p-Chip, use blockchain technology to authenticate data that can trace the cheese as far back as the producer of the milk used. The chips have been in advanced testing on more than 100,000 Parmigiano wheels for more than a year. The consortium of producers wants to be sure the chips can stand up to Parmigiano’s aging requirement, which is a minimum of one year and can exceed three years for some varieties.
Drugmaker Merck KGaA will soon begin using the chips, which are also being tested in the automotive industry to guarantee the authenticity of car parts. The chips could eventually be used on livestock, crops or medicine stored in liquid nitrogen.
“We don’t want to be known as the company accused of tracking people,” said Eibon. “I ate one of the chips and nobody is tracking me, except my wife, and she uses a different method.”
🧫 Ginkgo Bioworks Announces Collaboration with Merck to Improve Biologic Manufacturing
Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new collaboration with Merck, known as MSD outside of the United States and Canada, focused on improving biologic manufacturing.
Ginkgo will apply its expertise and capabilities in cell engineering, ultra high-throughput multiplexed screening, protein characterization and process optimization to improve production efficiency and increase yields. Under the terms of the collaboration, Ginkgo is eligible to receive, in aggregate, up to $490 million in upfront research fees, research milestone fees, option license payments and commercial milestone payments.